
Incyte shifts to multi-franchise biotech with 17% sales growth and key 2026 clinical readouts ahead
Incyte Corporation is evolving from relying mainly on its Jakafi drug to becoming a diversified biotech company with multiple late-stage pipeline assets. Its 2Q26 results showed a 17% increase in underlying net sales, broad portfolio growth, and stro...


